Cancer-Presented Work


American Association of Immunologists - IMMUNOLOGY 2017, Washington, DC, May 12-16, 2017


American Association for Cancer Research (AACR) 2017, Washington, DC, April 1-5, 2017


Keystone Symposium on Cancer Immunology and Immunotherapy, Whistler, British Columbia, March 19-23, 2017


Neoantigen Summit, Boston, November 15-17, 2016


Society of Immunotherapy of Cancer’s Annual Meeting & Associated Programs, National Harbor, November 9-13, 2016


Society for Immunotherapy of Cancer’s Annual Meeting & Associated Programs in National Harbor, November 7, 2015



 Antigen-Screening System - Perfecting the Promise of T Cell Therapies for Infectious Disease & Cancer 

Flechtner, JB (2016) Drug Development & Delivery epub June 2016

This article describes Genocea’s proprietary ATLAS™ technology, illustrating how finding the RIGHT targets of T cell responses matters for successful immunotherapies and vaccines.  The article describes how ATLAS had yielded an HSV-2 immunotherapy that has shown unprecedented efficacy in Phase 2 clinical trials and then introduces emerging cancer immunotherapy programs that highlight the ways ATLAS is poised to revolutionize immuno-oncology.